Lacrifill Occlusion: Reduce Eye Inflammation
- MINNEAPOLIS - Lacrifill, a canalicular gel, is showing promise in treating dry eye by reducing ocular surface inflammation, according to research presented at Optometry's Meeting.
- The study highlights the potential of Lacrifill (Nordic pharma), a hyaluronic acid derivative, to positively affect dry eye in unexpected ways, said study author Mile Brujic, OD, of...
- lacrifill, launched in the U.S. in April 2024, is administered via a cannula to introduce hyaluronic acid gel into the canalicular tract.
Lacrifill, a groundbreaking canalicular gel, is making waves in dry eye treatment by actively reducing ocular surface inflammation. A recent study, presented at Optometry’s Meeting, reveals that this hyaluronic acid derivative offers unexpected benefits. administered via cannula, Lacrifill, launched in the U.S. in April 2024,targets inflammation markers like MMP-9,leading to improvements in corneal staining and subjective symptoms. Patients who received Lacrifill after customary plugs experienced noticeable improvements. The results are promising, possibly establishing a new standard of care for many patients. This could very well be a singular and supplemental therapy for your particular dry eye concerns. news Directory 3 is reporting on this story. Discover what’s next in the treatment of dry eye.
Dry Eye Gel Reduces Ocular Inflammation
MINNEAPOLIS - Lacrifill, a canalicular gel, is showing promise in treating dry eye by reducing ocular surface inflammation, according to research presented at Optometry’s Meeting.
The study highlights the potential of Lacrifill (Nordic pharma), a hyaluronic acid derivative, to positively affect dry eye in unexpected ways, said study author Mile Brujic, OD, of Premier Vision Group in Ohio.
lacrifill, launched in the U.S. in April 2024, is administered via a cannula to introduce hyaluronic acid gel into the canalicular tract. Brujic noted that hyaluronic acid has properties that downregulate inflammation, including MMP-9, IL-6, and TNF.
brujic monitored dry eye patients for MMP-9, an inflammation marker, using InflammaDry (Quidel). Patients who received Lacrifill after customary dissolvable intracanalicular plugs experienced a disappearance of chronic corneal staining and an improvement in subjective symptoms.
“We saw that we could influence inflammation levels on the surface of the eye,” brujic said. He added that this was unexpected, as previous data suggested traditional punctal occlusion did not affect inflammation.
Brujic shared cases where Lacrifill improved inflammation levels, suggesting it is creating a new standard of care. He believes Lacrifill is becoming both a single-use and supplemental treatment for dry eye patients.